Title: siRNA Targeting Ras-Related Nuclear Protein
Number: 7,608,706
Filed: Nov. 8, 2006
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed."
Title: siRNA Targeting Survivin
Number: 7,608,707
Filed: Dev. 4, 2006
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," according to the patent's abstract. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes."
Title: Compositions and siRNAs for Inhibiting C/EBP-Beta
Number: 20090263354
Filed: March 10, 2009
Lead Inventor: Menachem Rubinstein, Yeda Research and Development
"The invention relates to C/EBP-beta and modulation of cell resistance or sensitivity to triggers of cell death," according to the patent application's abstract. Particularly, "it provides pharmaceutical compositions and siRNAs for inhibiting C/EBP-beta, thus decreasing resistance or enhancing sensitivity of cancer cells to a cancer therapy."
Title: Particulate Delivery Vehicles for Embryoid Bodies
Number: 20090263359
Filed: Feb. 4, 2009
Lead Inventor: Lino da Silva Ferreira, Massachusetts Institute of Technology
The invention "provides a vehicle for delivering various chemicals, compositions, and proteins to stem cells and embryoid bodies," the patent application's abstract states. "The vehicle may be biocompatible and biodegradable polymer microparticles. Typically, the particles will contain at least a growth factor for delivery to the embryoid bodies, and generally the growth factor induces differentiation of the cells in the embryoid body along a specific lineage."
The invention "also provides methods for directing differentiation of the cells in the embryoid body," the abstract noted.
The application specifically claims the use of the vehicles to delivery RNAi molecules.
Title: Method and Constructs for Delivering Double-Stranded RNA to Pest Organisms
Number: 20090263364
Filed: Oct. 25, 2005 PCT Filed: Oct. 25, 2005
Lead Inventor: Thierry Bogaert, DevGen
The invention "relates in [general] to RNAi and its use in gene silencing," the patent application's abstract states. "In particular, the …invention relates to methods and constructs for delivering double-stranded RNA to pest organisms."
Title: Methods and Compositions to Inhibit P2x7 Receptor Expression
Number: 20090264501
Filed: Aug. 30, 2005 PCT Filed: Aug. 30, 2005
Lead Inventor: Ana Jimenez, Sylentis
The invention, the patent application's abstract states, claims "methods and compositions for the down-regulation of P2X7 receptor expression or activity.
"Preferred compositions comprise" small interfering nucleic acid, the abstract notes. "The methods and compositions are useful in the treatment of diseases characterized by increased 112X7 receptor activity, such as neuronal degeneration, Alzheimer's disease, inflammatory diseases, and some cancers."
Title: Short Interference Ribonucleic Acids for Treating Allergic Disorders
Number: 20090264503
Filed: May 11, 2007 PCT Filed: May 11, 2007
Lead Inventor: Bor-Luen Chiang, Wholesome Biopharm
The invention, the patent application's abstract states, comprises "compounds, methods, and compositions for treating allergic diseases. In particular, [the invention involves] an isolated, double-stranded short interfering ribonucleic acid with a ribonucleotide sequence complementary to at least a portion of a target gene RNA such as an airway inflammation related-gene RNA, thereby resulting in the cleavage of the expressed target gene RNA via RNA interference mechanism."
Such a compound is "useful as a medicament for treating allergy by alleviating or minimizing airway inflammation of a subject," the abstract notes.
Title: RNA Interference-Mediated Inhibition of Human Immunodeficiency Virus Gene Expression Using Short Interfering Nucleic Acid
Number: 20090264504
Filed: Dec. 12, 2008
Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)
"This invention relates to compounds, compositions, and methods useful for modulating human immunodeficiency virus gene expression using short interfering nucleic acid molecules," the patent application's abstract states. "This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of human immunodeficiency virus gene expression and/or activity by RNA interference using small nucleic acid molecules. … The small nucleic acid molecules are useful in the treatment of HIV infection, AIDS, and/or diseases and conditions related to HIV infection and/or AIDS in a subject or organism."
Title: Methods and Compositions for RNAi-Mediated Inhibition of Gene Expression in Mammals
Number: 20090264505
Filed: Feb. 9, 2009
Lead Inventor: Mark Kay, Stanford University
The patent application, its abstract states, claims "methods and compositions … for modulating … expression of a target sequence in mammals and mammalian cells. In the subject methods, an effective amount of an RNAi agent … or a transcription template thereof … is introduced into a target cell. … Also provided are RNAi agent pharmaceutical preparations for use in the subject methods. The subject methods and compositions find use in a variety of different applications, including academic and therapeutic applications."
Title: Double-Helical Oligonucleotides Interfering with mRNA Used as Effective Anticancer Agents
Number: 20090264510
Filed: July 30, 2008
Lead Inventor: Maciej Wieczorek, Celon Pharma
The invention "relates to the application of double-helical oligonucleotides [such as] siRNA interfering with the mRNA of gene involved in carcinogenesis, particularly the Wnt1, Wnt2, or Her3 genes, the patent application's abstract states. "Such oligonucleotides may be modified chemically [and] used in conjunction with viral and non-viral vectors such as lipid complexes. Such oligonucleotides exhibit unusual anti-proliferative properties against tumor cells and may be used in anti-tumor treatment."
Title: Compositions and Methods for Inhibiting Expression of Factor VII Gene
Number: 20090264511
Filed: Dec. 10, 2008
Lead Inventor: Antonin de Fougerolles, Alnylam Pharmaceuticals
"The invention relates to a double-stranded ribonucleic acid for inhibiting the expression of the Factor VII gene," the patent application's abstract states.
Title: Conjugates and Compositions for Cellular Delivery
Number: 20090264636
Filed: Oct. 16, 2008
Lead Inventor: Chandra Vargeese, Sirna Therapeutics (Merck)
"This invention features conjugates, degradable linkers, compositions, methods of synthesis, and applications thereof, including cholesterol, folate, galactose, galactosamine, N-acetyl galactosamine, PEG, phospholipid, peptide, and human serum albumin-derived conjugates of biologically active compounds, including antibodies, antivirals, chemotherapeutics, peptides, proteins, hormones, nucleosides, nucleotides, non-nucleosides, and nucleic acids including enzymatic nucleic acids, DNAzymes, allozymes, antisense, dsRNA, siNA, siRNA, triplex oligonucleotides, 2,5-A chimeras, decoys, and aptamers," the patent application's abstract states.
Title: Method of Inhibiting Multiple Cytochrome P450 Genes with siRNA
Number: 20090265795
Filed: April 22, 2009
Inventor: William Baldwin, Clemson University
The invention, the patent application's abstract states, "relates to siRNAs that are targeted to RNAs encoding two or more enzymes of a subfamily of cytochrome P450 enzymes, along with vectors, cells, and kits comprising the siRNAs. The invention further relates to methods of decreasing expression of two or more CYP subfamily genes in a non-human animal, animals in which expression of two or more CYP subfamily genes has been decreased, and methods of using such animals to study the function of cytochrome P450 enzymes."